carlisle & Associates
generic drug updates News contact carlisle medical
news
Drug Release
Driving forward, making a difference
03/09/2020

First-Time Generic Release of Vimovo
Released: 03/09/2020
By: Carlisle Medical

First-Time Generic Release of Vimovo

The generic equivalent of Vimovo (naproxen/esomeprazole) is now available. Vimovo is FDA approved for the reduction of the risk of NSAID (non-steroidal anti-inflammatory) associated gastric ulcers in patients who require an NSAID for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in adults.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post First-Time Generic Release of Vimovo appeared first on Carlisle Medical.




03/06/2020

Carlisle Medical Monitoring Coronavirus Concerns
Released: 03/06/2020
By: Carlisle Medical

Monitoring Coronavirus Concerns - Carlisle Medical

Carlisle Medical continues to monitor concerns for potential disruptions in the availability of medications and medical equipment due to the Coronavirus (COVID-19). At this time, there are no specific medications listed as being in short supply due to the Coronavirus.

Carlisle Medical is in daily communication with its suppliers, pharmacy networks, and government agencies to assess and monitor all potential issues of the medication and equipment supply. The US Food and Drug Administration (FDA) is working with all drug manufacturers in evaluating and identifying future issues. In the case of a documented shortage, Carlisle Medical will do everything possible to assist in finding a viable alternative for an injured worker.

This Coronavirus concern is an evolving situation with constant changes. Carlisle Medical is committed to monitoring and assisting our partners during this time.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-supply-chain-update

The post Carlisle Medical Monitoring Coronavirus Concerns appeared first on Carlisle Medical.




03/03/2020

FDA Approves Three Drugs for OTC Use
Released: 03/03/2020
By: Carlisle Medical

FDA Approves Three Drugs for OTC Use

Last week, the FDA approved three medications for over-the-counter (OTC) use through a process called Rx-to-OTC switch. This means the medications can be purchased without a prescription. The Rx-to-OTC switch process is typically initiated by the manufacturer of the prescription medication. For this Rx-to-OTC switch to be approved by the FDA, the manufacturer must show that the medication can be used safely and effectively by a consumer without supervision of a healthcare professional. This includes approval of proposed labeling for the products.  The approved FDA medications are Voltaren Arthritis Pain, Pataday Once Daily Relief and Pataday Twice Daily Relief.

The prescription product Voltaren Gel 1% was first approved by the FDA in 2007 with an indication for the relief of osteoarthritis pain of joints amenable to topical therapy, such as ankle, elbow, foot, hand, knee, and wrist. Voltaren Gel 1% is currently available as a generic prescription product, diclofenac sodium topical gel 1%.  The approved OTC item will be marketed as Voltaren Arthritis Pain and will be the same strength as the current prescription product.

Pataday Once Daily Relief (olopatadine HCL ophthalmic solution/drops, 0.2%) was approved as Pataday in 2004 for the treatment of ocular itching associated with allergic conjunctivitis.

Pataday Twice Daily Relief (olopatadine HCL ophthalmic solution/drops, 0.1%) was first approved by the FDA as the prescription product Patanol in 1996 for the treatment of allergic conjunctivitis which presents as redness and itching of the eyes.

Both Pataday OTC products are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander.

All three medications will be marketed as nonprescription drugs within the U.S. and will no longer be available as prescription drugs. Those who currently take prescription versions of these medications and have questions about the Rx-to-OTC switch, should speak with their health care provider.

For more information regarding these FDA approvals, visit the FDA website at: https://www.fda.gov/news-events/press-announcements/fda-approves-three-drugs-nonprescription-use-through-rx-otc-switch-process

The post FDA Approves Three Drugs for OTC Use appeared first on Carlisle Medical.




01/31/2020

Generic Zohydro Is Now Available
Released: 01/31/2020
By: Carlisle Medical

Generic Zohydro Is Now Available

The generic formulation of Zohydro, hydrocodone bitartrate ER, has been released by Macoven Pharmaceuticals. Zohydro (hydrocodone bitartrate ER) is a Schedule II opioid. Zohydro is FDA approved for the management of pain, severe enough to require daily, around the clock, long term opioid treatment, where alternative treatment options are inadequate. Zohydro is dosed every twelve hours and the generic is available in multiple strengths (10mg, 15mg, 30mg, 40mg, and 50mg). Zohydro contains a combination of 20% immediate release and 80% extended-release hydrocodone, using its patented BeadTek technology.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post Generic Zohydro Is Now Available appeared first on Carlisle Medical.




12/31/2019

Generic Drug Update
Released: 12/31/2019
By: Carlisle Medical

December 2019 Generic Drug Update

Launch of Generic Travatan Z

A generic is now available for the ophthalmic drug Travatan Z (travoprost). Travatan is FDA approved for the treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.  Travoprost is available in 2.5ml and 5ml bottles.

 

First Time Generic Approvals

The FDA approved several first-time generic medications in late 2019. Below are some of the drugs that received first time generic approvals this quarter.

  • Eliquis – The FDA approved two applications for generic Eliquis.  Eliquis (apixaban) is an anticoagulant approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Eliquis is also used in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) to reduce the risk of recurrent DVT or PE following initial therapy. Eliquis is also used postoperatively in patients following hip or knee replacement surgery to prevent DVT or PE. The approved applications were from Micro Labs Limited and Mylan Pharmaceuticals Inc. The release dates of the generic formulations are currently unknown.

 

  • Latuda – The FDA approved an application from Lupin Pharmaceuticals for generic Latuda. Latuda (lurasidone) is an atypical antipsychotic approved to treat bipolar depression and schizophrenia. The release date of the generic formulation is currently unknown.

 

  • Viibryd – Teva Pharmaceuticals received FDA approval for their application for generic Viibryd (vilazodone). Viibryd is FDA approved for the treatment of major depressive disorder. The release date of the generic formulations is currently unknown.

 

“First generics” are the first approval by the FDA for a drug manufacturer to market a generic medication. It is important to note that a first generic approval does not indicate that the generic formulation will be available on or soon after the approval date. The actual market release of the generic drug product may be much farther in the future. As always, Carlisle Medical will monitor and make further announcements when the generic medications are available on the market.

The post Generic Drug Update appeared first on Carlisle Medical.




12/30/2019

FDA Approves New Migraine Treatments
Released: 12/30/2019
By: Carlisle Medical

FDA Approves New Migraine Treatments

Two new medications for the treatment of acute migraine with or without aura in adults were approved by the U.S. Food and Drug Administration (FDA) — Ubrelvy (ubrogepant) and Reyvow (lasmiditan). These new medications are not indicated for the prevention of migraine headaches.

Ubrelvy (ubrogepant) is the first oral medication in its class, calcitonin gene-related peptide receptor antagonists (CGRP).  Approval for Ubrelvy was granted to Allergan USA, Inc. Other CGRP-related medications on the market are monoclonal antibodies which must be injected by the user and are used as preventative therapy. These include medications such as Emgality, Aimovig, and Ajovy.  The Official Disability Guidelines (ODG) list the injectable CGRP medications as not recommended for first or second line therapies for preventative migraine treatment.

Reyvow (lasmiditan)is the first medication in a new drug class for the acute treatment of migraine headaches.  Approval was granted to Eli Lilly and Company, whom states that Reyvow has a unique mechanism of action and is the first and only FDA-approved 1F serotonin receptor agonist.

Carlisle Medical will continue to monitor the development and release of Ubrelvy and Reyvow. Pricing for these medications is not yet available and their anticipated release is in the first quarter of 2020. Current treatments for acute migraine headaches include medications such as non-steroidal anti-inflammatory drugs (NSAIDS) and triptans such as Imitrex (sumatriptan).

The post FDA Approves New Migraine Treatments appeared first on Carlisle Medical.




12/23/2019

FDA Releases Warning Regarding Gabapentin and Pregabalin
Released: 12/23/2019
By: Carlisle Medical

FDA Releases Warning Regarding Gabapentin and Pregabalin

The FDA recently released a warning for the medications, gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR).  The FDA warned that serious breathing difficulties may occur in patients using these medications who have respiratory risk factors. These risk factors include the use of opioids and other drugs that may depress the central nervous system (anti-anxiety medications, antidepressants, antihistamines). Patients who have certain medication conditions such as chronic obstructive pulmonary disease (COPD) may also be at an increased risk due to reduced lung function. Elderly patients may also be at an increased risk for breathing issues while using these medications.

Gabapentin and pregabalin are FDA-approved to treat several conditions, including seizures and neuropathic pain. These medications, often called gabapentinoids, are often prescribed in the realm of workers’ compensation. The FDA states that both the prescribed medicinal use and misuse and abuse have been growing for these drugs. The combination of gabapentin or pregabalin with other central nervous system depressants has also increased. The FDA does state that there is less evidence supporting the risk of serious breathing difficulties in healthy individuals taking gabapentin or pregabalin alone and they will continue to monitor these medications.

The FDA is requiring new warnings regarding the risk of respiratory depression be added to current prescribing information for these medications. The FDA is also requiring drug manufacturers to conduct clinical trials to further evaluate the abuse potential of these gabapentinoids, especially in combination with opioids since misuse and abuse of these two drug classes is increasing.

Carlisle Medical will continue to monitor for future updates regarding these medications. The link to the FDA communication can be found below.

https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin

The post FDA Releases Warning Regarding Gabapentin and Pregabalin appeared first on Carlisle Medical.




09/25/2019

FDA Alert Concerning Ranitidine Products
Released: 09/25/2019
By: Carlisle Medical

FDA Alert Concerning Ranitidine Products

By: Heidi Dufrene, Pharmacy Director

Earlier this month, the U.S. Food and Drug Administration (FDA) released a statement alerting patients and health care providers that some formulations of ranitidine contain an impurity classified as a probable human carcinogen, NDMA. Ranitidine, the generic form of Zantac, is an H2 (histamine) blocker and is FDA approved to treat heartburn, peptic ulcer disease and gastroesophageal reflux disease (GERD). Ranitidine is available as a prescription medication and over-the-counter (OTC).

NDMA, N-nitrosodimethylamine, is a known environmental contaminant found in water and foods, including meats, dairy products, and vegetables. It is classified as a probable human carcinogen based on laboratory test results. NDMA was an issue with a previous recall of certain blood pressure medications listed as Angiotensin II Receptor Blockers (ARBs) such as losartan and valsartan.

The FDA has announced a consumer-level recall of certain lots of ranitidine manufactured by Sandoz. In addition, the pharmaceutical company, Novartis, has halted distribution of its ranitidine products, as a precaution pending the results of the FDA’s investigation.  Anyone who is taking ranitidine and is concerned should contact their health care provider before stopping any medications. Those taking OTC ranitidine can switch to another OTC medication for heartburn.

For further information, please see below:

For questions regarding the Sandoz recall, patients can call 800-525-8747.

The statement alerting patients and health care professionals of NDMA found in samples of ranitidine may be found at:https://www.fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine?elq_mid=21733&elq_cid=2282725

Click Here To Contact Carlisle Medical

The post FDA Alert Concerning Ranitidine Products appeared first on Carlisle Medical.




09/16/2019

The U.S. DEA Proposes Production Cuts to Five Opioids in 2020
Released: 09/16/2019
By: Carlisle Medical

The U.S. DEA Proposes Production Cuts to Five Opioids in 2020

The U.S. DEA (Drug Enforcement Administration) released a Notice of Proposed Rulemaking in the Federal Register this week. The agency has proposed reducing production quotas for five opioids (fentanyl – 31%, hydrocodone -19%, hydromorphone -25%, oxycodone – 9% and oxymorphone – 55%) in 2020.

The DEA sets aggregate production quotas each year for Schedule I and II controlled substances. These five opioids were subject to special scrutiny due to enactment of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT Act). The SUPPORT Act requires the DEA to estimate the amount of diversion of certain substances in the U.S. and to reduce quotas appropriately.

The DEA also proposes to increase the amount of marijuana allowed for research from 2,450 kilograms to 3,200 kilograms. This increase is being proposed to meet the need created by increased approvals of marijuana research. The number of individuals registered with the DEA to conduct marijuana research has risen from 384 in 2017 to 542 in 2019.

The DEA will accept comments on this proposal through October 15, 2019.  After this time, the DEA will publish a notice later in the year stating the established aggregate production quotas.

For further information, visit the DEA’s website at: https://www.aha.org/news/headline/2019-09-13-dea-proposes-reducing-five-opioid-production-quotas-2020

The post The U.S. DEA Proposes Production Cuts to Five Opioids in 2020 appeared first on Carlisle Medical.




07/30/2019

Generic Launch of Rozerem
Released: 07/30/2019
By: Carlisle Medical

Generic Launch of Rozerem

The generic equivalent of Rozerem (Ramelteon) is now available. Rozerem is FDA approved for the treatment of insomnia, characterized by difficulty with sleep onset.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or atpharmacy@carlislemedical.com.

The post Generic Launch of Rozerem appeared first on Carlisle Medical.




07/24/2019

Launch of Generic Lyrica
Released: 07/24/2019
By: hummingbird

Launch of Generic Lyrica

The U.S. Food and Drug Administration (FDA) has approved the launch of generic Lyrica (pregabalin). Lyrica is a non-opioid drug used to treat neuropathic pain.

The FDA has initially granted approval for the generic version of Lyrica to nine drug companies, to include Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc. and Teva Pharmaceuticals. It is anticipated that over time, other manufacturers will enter the market, which will have a favorable impact on cost.

Generic prescription drugs approved by the FDA have the same quality and strength as brand name drugs. Generic drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Carlisle Medical encourages generic prescriptions and will notify prescribing physicians of the generic Lyrica as it becomes available in the market.

If you have any questions, please do not hesitate to contact us at pharmacy@carlislemedical.com.

The post Launch of Generic Lyrica appeared first on Carlisle Medical.




07/16/2019

Gabapentin to Become A Controlled Substance in Alabama
Released: 07/16/2019
By: hummingbird

By: Heidi Dufrene, PharmD

 

Recently, the Alabama State Committee of Public Health voted to change Gabapentin to a Schedule V medication.  This ruling will become effective November 18, 2019, giving pharmacies and other health care providers adequate time to implement necessary changes. Once the change to a Schedule V has occurred, prescriptions for Gabapentin can contain no more than five refills, expire within six months and must be reported to the Alabama state prescription monitoring database.

 

Alabama follows several other states which have already changed Gabapentin to a controlled substance, including Kentucky, Tennessee, West Virginia, Michigan and Virginia.

The post Gabapentin to Become A Controlled Substance in Alabama appeared first on Carlisle Medical.




06/21/2019

Launch of Generic Lyrica
Released: 06/21/2019
By: hummingbird

Launch of Generic Lyrica

The generic formulation of Lyrica, pregabalin, is expected to be released around July 1, 2019. Lyrica is indicated for neuropathic pain and is a commonly prescribed medication in workers’ compensation. The manufacturer of Lyrica, Pfizer Inc., previously received a six-month extension on Lyrica’s patent due to the FDA’s decision to grant pediatric exclusivity for use as adjunctive therapy in pediatric patients with partial onset seizures.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post Launch of Generic Lyrica appeared first on Carlisle Medical.




06/10/2019

Gabapentin to Become a Controlled Substance in Virginia
Released: 06/10/2019
By: hummingbird

Gabapentin to Become a Controlled Substance in Virginia

The 2019 Virginia General Assembly recently passed a new bill that will classify gabapentin as a Schedule V substance starting July 1, 2019. Currently, gabapentin is classified as a Schedule VI drug of concern. This change in schedule will require gabapentin to be reported to the Virginia Prescription Monitoring Program as a schedule V substance. Prescriptions for gabapentin will expire after six months and may have a maximum of five refills. Virginia will join several other states that have already classified gabapentin as a controlled substance: Kentucky, Tennessee, West Virginia, and Michigan. Gabapentin is currently not a controlled substance under federal law.

Gabapentin is often prescribed to treat conditions such as neuropathic pain, restless leg syndrome, and epilepsy. Gabapentin was first brought to the market as brand Neurontin in 1993 and since then has become widely used in the treatment of pain. Abuse of gabapentin has become more prevalent in recent years and has increased with the serious nature of the opioid crisis in the United States. It is most often abused by polydrug users who combine it with other substances to increase desired effects.

The post Gabapentin to Become a Controlled Substance in Virginia appeared first on Carlisle Medical.




04/26/2019

Launch of Generic Vesicare
Released: 04/26/2019
By: hummingbird

By: Heidi Dufrene, PharmD

The generic equivalent of Vesicare (Solifenacin succinate) is now available. Vesicare is FDA approved for the treatment of an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post Launch of Generic Vesicare appeared first on Carlisle Medical.




03/13/2019

Launch of Generic Flector Patch
Released: 03/13/2019
By: Heidi Dufrene, PharmD

The generic equivalent of Flector Patch (Diclofenac Epolamine) is now available. The Flector Patch is FDA approved for the topical treatment of acute pain due to minor strains, sprains, and contusions.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/11/2019

Launch of Generic Amrix
Released: 03/11/2019
By: Heidi Dufrene, PharmD

The generic equivalent of Amrix (cyclobenzaprine ER) is now available. Amrix is FDA-approved to treat muscle spasms and will be available in both 15mg and 30mg strengths.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/05/2019

Launch of Generic Ranexa
Released: 03/05/2019
By: Heidi Dufrene, PharmD

The generic equivalent of Ranexa (ranolazine) is now available. Ranexa is FDA-approved to treat chronic angina and is available in both the 500mg and 1000mg strengths.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/25/2019

Launch of Generic Suboxone Film
Released: 02/25/2019
By: Heidi Dufrene, PharmD

The generic equivalent of Suboxone sublingual film (buprenorphine/naloxone) is now available. Suboxone is FDA-approved to treat opioid dependence. The generic film is available in the following strengths: 2/0.5mg, 4/1mg, 8/2mg, and 12/3mg.

Suboxone may be an option for those struggling with opioid dependence and should be part of a treatment plan that includes psychosocial support, along with medication-assisted therapy.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/06/2019

Launch of Generic Advair
Released: 02/06/2019
By: Heidi Dufrene, PharmD

The generic equivalent of Advair (fluticasone/salmeterol) was recently approved by the FDA and is expected to be available later this month. Advair is manufactured by GlaxoSmithKline and is FDA-approved for the treatment of asthma and COPD.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



01/04/2019

Drug Patents Expiring in 2019
Released: 01/04/2019
By:

The list below is comprised of prescription medications slated for drug patent expirations in 2019. As these dates approach, Carlisle Medical will seek opportunities to transition claimants to the generic medication versions as they become available. Please note, these are anticipated generic launch dates and are subject to change.

Brand Name: Latuda
• Generic Name: Lurasidone
• Patent Expiration Date: January 2019
• Used to treat schizophrenia or bipolar disorder, also known as manic-depression.

Brand Name: Restasis
• Generic Name: Cyclosporine ophthalmic emulsion
• Patent Expiration Date: 2019
• Used to increase tear productions when suppressed tear production is presumed to be due to keratoconjunctivitis sicca-associated ocular inflammation.

Brand Name: Ranexa
• Generic Name: Ranolazine
• Patent Expiration Date: February 2019
• Used to treat chronic chest pain.

Brand Name: Vesicare
• Generic Name: Solifenacin succinate
• Patent Expiration Date: May 2019
• Used to treat overactive bladder.

Brand Name: Lyrica
• Generic Name: Pregabalin
• Patent Expiration Date: July 2019
• Used to treat nerve pain from diabetes, shingles, spinal cord injury, and fibromyalgia. It is also used to control seizures in epilepsy.

Brand Name: Suboxone sublingual film
• Generic Name: Buprenorphine/Naloxone sublingual film
• Patent Expiration Date: 2020 or earlier.
• Used to treat certain types of drug dependence.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



11/30/2018

Launch of Generic Staxyn
Released: 11/30/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Staxyn (Vardenafil) has recently launched. Staxyn is FDA-approved to treat erection dysfunction and is available in a 10mg orally disintegrating tablet. Staxyn is one of several erectile dysfunction medications that have recently become available in generic, such as Viagra (Sildenafil), Levitra (Vardenafil), and Cialis (Tadalafil).

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.





11/02/2018

Launch of Generic Levitra Tablets
Released: 11/02/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Levitra (Vardenafil) has recently launched in the 2.5mg, 5mg, 10mg and 20mg strengths. Levitra is FDA-approved to treat erection dysfunction. Levitra is one of several erectile dysfunction medications that have recently become available in generic, such as Viagra (Sildenafil) and Cialis (Tadalafil).

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



10/19/2018

Launch of Generic Androgel 1.62%
Released: 10/19/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Androgel 1.62% (testosterone) has recently launched in the metered dose pump and unit-dose packets. Androgel is FDA-approved to treat hypogonadism, a condition in which there is a reduction or absence of endogenous sex hormones, such as testosterone. Androgel and other testosterone replacement products are often prescribed in workers’ compensation due to the decrease in testosterone levels in males from chronic opioid usage.


Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.



If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



10/02/2018

Launch of Generic Cialis Tablets
Released: 10/02/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Cialis (Tadalafil) has recently launched in the 2.5mg, 5mg, 10mg and 20mg strengths. Cialis is FDA-approved to treat erection dysfunction and benign prostatic hyperplasia (BPH). BPH is the enlargement of the prostate gland in men. Cialis can be prescribed to improve urine flow and reduce BPH symptoms. Patients may experience both BPH and erectile dysfunction, for which Cialis may be an appropriate treatment option.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



06/15/2018

Launch of Generic Suboxone
Released: 06/15/2018
By: Carl Richie, Pharmacy Manager

The generic equivalent of Suboxone (buprenorphine and naloxone) sublingual film (applied under the tongue) has been approved by the U.S. Food and Drug Administration (FDA). Suboxone is a prescription medicine indicated for treatment of opioid dependence.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783, option 1, or at pharmacy@carlislemedical.com.



05/23/2018

Launch of Generic Welchol Tablets
Released: 05/23/2018
By: Carl Richie, Pharmacy Manager

The generic equivalent of Welchol (Colesevelam) has recently been launched. Welchol is a prescription medicine used to lower cholesterol in patients who are at risk of heart disease or stroke. This medicine is only for patients whose cholesterol level is not controlled by diet. It is also used in combination with diet and exercise to help lower blood sugar in adults with Type 2 Diabetes.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 1-800-553-1783 or at pharmacy@carlislemedical.com.



02/21/2018

Launch of Generic Namenda XR Tablets
Released: 02/21/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Namenda XR (memantine hydrochloride) has just been launched in the 7mg, 14mg, 21mg and 28mg strengths. Namenda reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease. Namenda XR (memantine hydrochloride) is used to treat moderate to severe dementia of the Alzheimer's type.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/21/2018

Launch of Generic Treximet Tablets
Released: 02/21/2018
By: Heidi Dufrene, PharmD

The generic equivalent of Treximet (sumatriptan/naproxen sodium) has just been launched. Treximet is a prescription medicine that contains sumatriptan and naproxen sodium (an NSAID -- non-steroidal anti-inflammatory drug.) It is used to treat acute migraine headaches, with or without aura, in patients twelve years of age and older.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/06/2018

Drug Patents Expiring in 2018
Released: 02/06/2018
By:

The list below is comprised of prescription medications slated for drug patent expirations in 2018. As these dates approach, Carlisle Medical will seek opportunities to transition claimants to the generic medication versions as they become available. Please note, these are anticipated generic launch dates and are subject to change.


• Brand Name: Treximet
• Generic Name: Sumatriptan/Naproxen
• Patent Expiration Date: February 2018
• Used to treat migraines with or without aura.

• Brand Name: Sensipar
• Generic Name: Cinacalcet
• Patent Expiration Date: March 2018
• Used to treat patients with chronic kidney disease who are on dialysis. It is also used to treat high levels of calcium in the blood of patients with certain parathyroid gland problems.

• Brand Name: Spiriva
• Generic Name: Tiotropium
• Patent Expiration Date: July 2018
• Used for maintenance treatment of chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema.

• Brand Name: Tekturna
• Generic Name: Aliskiren/hctz
• Patent Expiration Date: July 2018
• Used to treat high blood pressure.

• Brand Name: Cialis
• Generic Name: Tadalafil
• Patent Expiration Date: September 2018
• Used to treat erection problems in men. It is also used for enlargement of the prostate gland in men, a condition called benign prostatic hyperplasia or BPH.

• Brand Name: Symbicort
• Generic Name: Budesonide/formoterol
• Patent Expiration Date: September 2018
• Used to treat asthma. It is also used to treat chronic obstructive pulmonary disease, including chronic bronchitis or emphysema.

• Brand Name: Levitra
• Generic Name: Vardenafil
• Patent Expiration Date: October 2018
• Used for the treatment of erectile dysfunction (ED) in men.

• Brand Name: Staxyn
• Generic Name: Vardenafil
• Patent Expiration Date: October 2018
• Used for the treatment of erectile dysfunction (ED) in men.

• Brand Name: Vesicare
• Generic Name: Solifenacin
• Patent Expiration Date: October 2018
• Used to treat overactive bladder.

• Brand Name: Fortesta
• Generic Name: Testosterone
• Patent Expiration Date: November 2018
• Used in males to treat low testosterone levels.

• Brand Name: Lyrica
• Generic Name: Pregabalin
• Patent Expiration Date: December 2018
• Used to treat nerve pain from diabetes, shingles, spinal cord injury, and fibromyalgia. It is also used to control seizures in epilepsy.

• Brand Name: Rapaflo
• Generic Name: Silodosin
• Patent Expiration Date: December 2018
• Used to treat enlargement of the prostate gland in men, a condition called benign prostatic hyperplasia or BPH.


Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



12/12/2017

Launch of Generic Viagra
Released: 12/12/2017
By: Heidi Dufrene, PharmD

The generic equivalent of Viagra (Sildenafil) has just been released, following FDA approval. Pfizer Inc. has held exclusive rights to the erectile dysfunction (ED) medication since 1998. The generic formulation is now available in 25mg, 50mg, and 100mg strengths.

Since Viagra entered the market almost twenty years ago, several other companies have released medications to treat ED such as Cialis, Levitra and Staxyn. Viagra is the first of these ED drugs to go generic. Currently, Pfizer and Teva are the only two generic manufacturers for Sildenafil. However, by summer more generic manufacturers are expected to enter the market which is expected to significantly impact price.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



11/17/2017

Generic Viagra to be Released Before End of the Year
Released: 11/17/2017
By: Heidi Dufrene, PharmD

The generic equivalent of Viagra (Sildenafil) is expected to be released December 11, 2017. Viagra has held exclusive rights to the erectile dysfunction (ED) medication since 1998. The generic formulation will be available in 25mg, 50mg, and 100mg strengths. Since Viagra entered the market almost twenty years ago, several other companies have released medications to treat ED such as Cialis, Levitra and Staxyn. Viagra is the first of these ED drugs to go generic.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



07/25/2017

Launch of Generic Relpax
Released: 07/25/2017
By: Heidi Dufrene, PharmD

The generic equivalent of Relpax (Eletriptan) has just been released, following FDA approval. Relpax is FDA-approved for the acute treatment of migraine with or without an aura in adults. Eletriptan will be available in 20 and 40mg strengths.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



05/31/2017

Launch of Generic Strattera
Released: 05/31/2017
By: Heidi Dufrene, PharmD

The generic equivalent of Strattera (Atomoxetine) has just been released, following FDA approval. Strattera is FDA-approved to treat ADHD (Attention deficit hyperactivity disorder). Strattera is available in several strengths, (10, 18, 25, 40, 60, 80 and 100mg) all of which will be available in the generic formulation.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.

Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



05/31/2017

Launch of Generic Butrans
Released: 05/31/2017
By: Heidi Dufrene, PharmD

The FDA has recently approved the generic equivalent of Butrans (Buprenorphine) transdermal patches. Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Butrans should be reserved for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Butrans is not indicated as an as-needed analgesic.[i] The generic formulation will be available in 5mg, 10mg, 15mg and 20mg. Butrans is also available in a 7.5mg strength that is not included in the current generic release at this time.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

_____________________

[1] 1. Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma; December 2016.



04/27/2017

Launch of Generic Vytorin
Released: 04/27/2017
By:

The generic equivalent of Vytorin (ezetimibe/simvastatin) has just been released, following FDA approval. Vytorin is indicated for the treatment of primary hyperlipidemia and homozygous familial hypercholesterolemia. Vytorin is a combination drug combining the active ingredients of Zetia (ezetimibe) and Zocor (simvastatin). Generic Vytorin is available in the following strengths: 10/10mg, 10/20mg, 10/40mg, and 10/80mg.


All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.


Please contact us at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions on this announcement or if our pharmacy staff may assist you in any way.



03/01/2017

Launch of Generic Pristiq
Released: 03/01/2017
By: Carl Richie, Pharmacy Director

The generic equivalent of Pristiq (Desvenlafaxine) has just been released, following FDA approval. Pristiq is used to treat major depressive disorder.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.

If you have any questions on this announcement or if our pharmacy staff may assist you in any way, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



01/06/2017

Generic Oxycontin ER -- Temporarily Unavailable in Certain Strengths
Released: 01/06/2017
By: Carl Richie, Pharmacy Director

The generic version of Oxycontin ER (oxycodone extended-release) is currently not available in the 10mg and 20mg strengths. According to the manufacturer, Teva Pharmaceuticals, these strengths are currently unavailable and a time frame to resume production has not yet been determined. The generic version of Oxycontin ER (oxycodone extended-release) continues to be available in the 40mg and 80mg strengths.

Carlisle Medical encourages physicians to prescribe generic medications when they are available. We will continue to monitor the availability of all strengths of the generic Oxycontin ER and will report any updates we receive.

If you have any questions or if we may assist you in any way, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



12/27/2016

Launch of Generic EpiPen
Released: 12/27/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of EpiPen (epinephrine) is now available from Mylan. The EpiPen is used to treat severe/life-threatening allergic reactions to insect stings/bites, foods, drugs and other allergens. Mylan is also the manufacturer of the brand EpiPen and states the generic is equivalent to the EpiPen Auto-Injector, including device functionality and drug formulation, and is offered at half the wholesale acquisition cost of the brand. The generic epinephrine auto-injector is available in 0.15mg/0.3ml and 0.3mg/0.3ml dosage strengths.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



12/12/2016

Launch of Generic Zetia
Released: 12/12/2016
By: Carl Richie, Pharmacy Director

The FDA has recently approved the generic equivalent of Zetia (ezetimibe). Zetia is used to treat high cholesterol by reducing the amount of cholesterol absorbed by the body. Zetia is manufactured in the 10mg strength and the generic ezetimibe is now available.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



11/02/2016

Launch of Generic Seroquel XR
Released: 11/02/2016
By: Carl Richie, Pharmacy Director

The FDA has recently approved the generic equivalent of Seroquel XR (quetiapine fumarate extended-release tablets). Seroquel XR is used to treat psychiatric conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder.) It may also be prescribed, along with other medications, for depression. Quetiapine works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur. The generic equivalent of Seroquel XR will be available in a variety of strengths, to include 50mg, 150mg, 200mg, 300mg and 400mg.
Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



10/28/2016

EpiPen Alternative Is Available
Released: 10/28/2016
By: Carl Richie, Pharmacy Director

A generic equivalent of Adrenaclick (epinephrine auto-injector) is available from Impax Laboratories. The epinephrine auto-injector is an emergency injection of epinephrine. It is used to treat severe allergic reactions to insect stings/bites, foods, drugs and other allergens. The epinephrine auto-injector by Impax Laboratories is available in 0.15mg and 0.3mg strengths. The 0.3mg strength is a generic equivalent to EpiPen and has a current cost savings of approximately 38%, when compared to the brand EpiPen. It is anticipated that other generic epinephrine auto-injectors will be introduced to the market by other manufacturers, pending FDA approval. The epinephrine auto-injector is designed for single-dose use by patients and does not take the place of emergency medical care.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



10/27/2016

Launch of Generic Benicar and Benicar HCTZ
Released: 10/27/2016
By: Carl Richie, Pharmacy Director

The FDA has recently approved the generic equivalent of Benicar and Benicar HCTZ (olmesartan medoxomil and olmesartan medoxomil hydrochlorothiazide). Benicar is used to treat high blood pressure by keeping the blood vessels from narrowing and improving blood flow.
Generic prescription drugs approved by the FDA are required to have the same active ingredient, strength, dosage form and route of administration as the brand name product. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.
If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



06/01/2016

Launch of Generic Nuvigil
Released: 06/01/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Nuvigil (armodafinil) has just been released, following FDA approval. Nuvigil is used to treat excessive sleepiness caused by sleep apnea, narcolepsy or shift work sleep disorder.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Nuvigil is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or pharmacy@carlislemedical.com



05/03/2016

Launch of Generic Equivalent: Crestor (Rosuvastatin)
Released: 05/03/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Crestor (rosuvastatin) has just been released, following FDA approval. Crestor is used to lower cholesterol and to slow down plaque buildup in arteries.
All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.
If you have any questions on this announcement or if our pharmacy staff may assist you in any way, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



04/28/2016

Brand-name Vivlodex™ and Generic MOBIC
Released: 04/28/2016
By: Christina Bond

Vivlodex™ is a low-dose nonsteroidal anti-inflammatory drug (NSAID) new option for people suffering from the degenerative joint condition, osteoarthritis (OA). Recently approved by the US Food and Drug Administration (FDA), this pain treatment contains SoluMatrix® meloxicam, which is a NSAID ingredient commonly found in other OA pain management options.
Currently, Vivlodex™ is available in 5mg and 10mg doses. Generic alternatives, such as MOBIC (Meloxicam) offer an affordable dose, between the aforementioned amounts (7.5mg) and a larger 15mg pain management treatment.
At this time, Carlisle Medical recommends that osteoarthritis pain be treated with available generic drugs within the NSAID class as first-line therapy for an effective treatment regimen.

Current Official Disability Guidelines (ODG) state, “there is no evidence to recommend one drug in this class (NSAIDs) over another based on efficacy… there appears to be no difference in terms of pain relief (between different NSAIDs).” Vivlodex™ is considered an “N” drug on the ODG formulary. Drugs listed as “N” drugs mean they are not preferred by the ODG organization to initially treat patients.



03/28/2016

Launch of Generic Voltaren 1% Gel
Released: 03/28/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Voltaren 1% topical gel (diclofenac sodium) has just been released, following FDA approval. Voltaren 1% topical gel is used to treat joint pain by reducing hormones in the body that cause inflammation and pain. Like the brand Voltaren, the generic diclofenac sodium 1% topical gel is available in a 100gm tube form.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Voltaren 1% topical gel is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/23/2016

Launch of Generic Frova
Released: 03/23/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Frova (frovatriptan succinate) has just been released, following FDA approval. Frova is used to treat acute migraine headaches with or without auras.

All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand-name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand-name drugs.

If you have any questions on this announcement or if our pharmacy staff may assist you in any way, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/23/2016

Launch of Generic Nasonex
Released: 03/23/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Nasonex (mometasone) has just been released, following FDA approval. Nasonex is used to treat the nasal symptoms of allergies. This includes congestion, sneezing and a runny nose.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs. Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Nasonex is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/15/2016

Launch of Generic Enablex
Released: 03/15/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Enablex (darifenacin) has just been released, following FDA approval. Enablex is used to reduce muscle spasms of the bladder and urinary tract. It is often prescribed to treat the symptoms of an overactive bladder and incontinence.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Enablex is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/02/2016

Launch of Generic Glumetza
Released: 02/02/2016
By: Carl Richie, Pharmacy Director

The generic equivalent of Glumetza (Metformin HCI ER) has just been released. Glumetza is an oral diabetes medicine prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. This medication is available in 500mg and 1000mg strengths.
All generic drugs approved by the FDA have the same quality, strength, purity and stability as brand name drugs. The generic manufacturing, packaging and testing sites must pass the same quality standards as those of brand name drugs.
If you have any questions on this announcement or if our pharmacy staff may assist you in any way, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



12/09/2015

Launch of Generic Patanol
Released: 12/09/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Patanol (olopatadine) has just been launched. Patanol is an antihistamine that reduces the natural chemical histamine in the body. It is used to treat itching, burning, redness, watering and other eye symptoms caused by allergic conditions.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Patanol (olopatadine) is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



10/12/2015

Launch of Generic Avodart
Released: 10/12/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Avodart 0.5mg (dutasteride) is now available. Avodart is a prescription medication prescribed to treat an enlarged prostate and works by blocking the conversion of testosterone into DHT (dihydrotestosterone), thereby decreasing the amount of DHT in the body.

Generic prescription drugs approved by the FDA are required to have the same active ingredient, strength, dosage form and route of administration as the brand name product. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Please contact the Carlisle pharmacy at 800-553-1783 or at pharmacy@carlislemedical.com if you have any questions.



09/04/2015

Launch of Generic ConZip
Released: 09/04/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of ConZip (tramadol hydrochloride extended-release) capsules is now available in 100, 200 and 300mg strengths. Tramadol is used for the management of moderate to moderately severe chronic pain. The extended-release capsules are used to provide around-the-clock treatment for pain for an extended period of time.

Generic prescription drugs approved by the FDA are required to have the same active ingredient, strength, dosage form and route of administration as the brand name product. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



07/13/2015

Launch of Generic Namenda Tablets
Released: 07/13/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Namenda (memantine hydrochloride) has just been launched in the 5mg and 10mg strengths. Namenda reduces the actions of chemicals in the brain that may contribute to the symptoms of Alzheimer's disease. Namenda (memantine hydrochloride) is used to treat moderate to severe dementia of the Alzheimer's type.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Namenda (memantine hydrochloride) is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



07/08/2015

Launch of Generic Axert Tablets
Released: 07/08/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Axert (almotriptan) has just been launched in the 6.25mg and 12.5mg strengths. Axert is used to treat migraine headaches. It helps to reduce pain and other symptoms of migraine headaches, including sensitivity to light and sound, nausea and vomiting. Axert (almotriptan) belongs to a group of drugs called triptans. It affects a certain natural chemical (serotonin) that constricts blood vessels in the brain. Axert (almotriptan) may also block other pain pathways in the brain.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Axert (almotriptan) is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



07/01/2015

Launch of Generic Aggrenox
Released: 07/01/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Aggrenox (aspirin/extended release dipyridamole) capsules has just been announced by Teva Pharmaceutical Industries Ltd. in the United States. Aspirin and extended release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due to a blood clot.

Generic prescription drugs approved by the FDA are required to have the same active ingredient, strength, dosage form and route of administration as the brand name product. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



06/23/2015

Launch of Generic Zyvox
Released: 06/23/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Zyvox (Linezolid) has just been released, following approval from the U.S. Food and Drug Administration (FDA). Zyvox is an antibiotic used to treat bacterial infections such as pneumonia and certain types of skin infections. Zyvox may also be used to treat infections that are resistant to other antibiotics.

Generic prescription drugs approved by the FDA are required to have the same active ingredient, strength, dosage form and route of administration as the brand name product. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



04/28/2015

Launch of Generic Abilify
Released: 04/28/2015
By: Carl Richie, Pharmacy Director

The generic equivalent of Abilify (Aripiprazole) has just been released in multiple strengths, following FDA approval. Abilify is an antipsychotic medication. It is used to treat schizophrenia and bipolar disorder. Abilify can also be prescribed in conjunction with other medications to treat depression disorder. The initial supply is expected to be limited until multiple manufacturers enter the market.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version Abilify is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



03/11/2015

Launch of Generic Naprelan CR Tablets
Released: 03/11/2015
By: Carl Richie, Pharmacy Manager

The generic equivalent of Naprelan CR tablets (naproxen sodium controlled release) has just been launched, following approval by the FDA (Food and Drug Administration.) Naprelan is a member of the nonsteroidal anti-inflammatory drugs (NSAIDs) group. It is designed to relieve pain and reduce joint stiffness and swelling.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Naprelan CR is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



02/17/2015

Launch of Generic Nexium
Released: 02/17/2015
By: Carl Richie, Pharmacy Manager

The generic equivalent of Nexium (esomeprazole) has been released, following FDA approval. Nexium treats gastroesophageal reflux disease (GERD) by reducing the amount of acid produced in the stomach. At the time of this announcement, one manufacturer has received the approval to market the generic. It is anticipated the initial demand of the generic esomeprazole will exceed the initial supply available. Consequently, pricing for the initial launch of the generic will be slightly less or equal to the price of the brand Nexium. As more manufacturers enter the market, the cost of the generic esomeprazole will decrease.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Nexium (esomeprazole) is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



02/04/2015

Over the Counter Flonase – Now Available
Released: 02/04/2015
By: Carl Richie, Pharmacy Manager

Over the counter (OTC) Flonase is now available in 60 and 120-spray sizes. Flonase (Fluticosone Propionate nasal spray) is used for symptoms of upper respiratory allergies and is formulated to provide 24-hour non-drowsy allergy relief.

With this release, Carlisle Medical will contact prescribing physicians to inform them the OTC version of Flonase is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



01/26/2015

Generic Nexium Approved by FDA
Released: 01/26/2015
By: Carl Richie, Pharmacy Manager

The FDA has recently approved the generic equivalent of Nexium (esomeprazole). Nexium treats gastroesophageal reflux (GERD) by reducing the amount of acid produced in the stomach. An official launch date has yet to be announced by the manufacturer.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



01/12/2015

Launch of Generic Colcrys 0.6mg
Released: 01/12/2015
By: Carl Richie, Pharmacy Manager

The generic equivalent of Colcrys 0.6mg (colchicine 0.6mg) has just been released, following FDA approval. Colcrys 0.6mg reduces the pain of gout flares and helps prevent future flairs.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



12/03/2014

Anticipated Launch of Generic Celebrex
Released: 12/03/2014
By: Carl Richie, Pharmacy Manager

It is anticipated the generic launch of Celebrex (celecoxib) is imminent, following approval by the U.S. Food and Drug Administration (FDA) earlier this year. Initially, the generic celecoxib will have 180-day marketing exclusivity by a limited number of manufacturers. During this exclusivity period, pricing may not vary significantly from the cost of the brand Celebrex. Once the exclusivity period has expired, it is anticipated that other manufacturers will enter the market, which will have a favorable impact on cost.

Generic prescription drugs approved by the FDA have the same quality and strength as brand-name drugs. Generic drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs. Celebrex (celecoxib) is a Non-Steriodal Anti-Inflammatory Drug (NSAID) used to treat pain or inflammation.

Carlisle Medical encourages generic prescriptions and will notify prescribing physicians of the generic celecoxib as part of our pharmacy management service, once it has been introduced. If you have any questions on this, please do not hesitate to contact us at pharmacy@carlislemedical.com or 800-553-1783.



10/27/2014

Launch of Generic Patanase®
Released: 10/27/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Patanase® (olopatadine) has just been launched, following FDA approval. Patanase® is an antihistamine which reduces sneezing, itching, watery eyes and runny nose.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



10/01/2014

Carlisle Pharmacy News -- Launch of Generic Oxycontin CR
Released: 10/01/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Oxycontin CR (Oxycodone HCl ER) has just been released, following FDA approval. Oxycontin CR is a Schedule II narcotic and is used to treat moderate to severe pain. Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Oxycontin CR is available. Our management makes a difference.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



09/30/2014

Launch of Generic Exforge®
Released: 09/30/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Exforge® (amlodipine besylate, valsartan) has just been released, following FDA approval. Exforge® is an angiotensin that relaxes the muscles in your heart for improved blood flow.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



09/17/2014

Launch of Generic Fortesta Gel Pump
Released: 09/17/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Fortesta Gel Pump (testosterone gel) has just been released, following FDA approval. Fortesta Gel Pump is used by adult men to treat the symptoms of low testosterone levels or no testosterone levels.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



08/25/2014

Carlisle Medical Pharmacy News -- Upcoming First Time Generic Releases
Released: 08/25/2014
By: Carl Richie, Pharmacy Manager

It is anticipated the following Brand medications will have a generic drug launched the third and fourth quarter of 2014. As new generics are launched, Carlisle Medical contacts prescribing physicians to make them aware. If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com
Brand Generic Name Use
Naprelean Naproxen Sodium Used to treat tendonitis, bursitis, gout, menstrual cramps, or mild to moderate pain.
Actonel (5mg, 30mg, 35mg) Risedronate Sodium Used to treat or prevent osteoporosis in men and women. It is also used to treat Paget's disease of bone.
Nuvigil Armodafinil Nuvigil is used to treat excessive sleepiness caused by sleep apnea, narcolepsy, or shift work sleep disorder.



08/06/2014

OTC Flonase Expected to Be Available in Early 2015
Released: 08/06/2014
By: Carl Richie, Pharmacy Manager

The FDA has recently approved Flonase Allergy Relief to be an OTC treatment for temporary relief of symptoms for upper respiratory allergies. Flonase is the first, and only, OTC nasal spray indicated for relief of all allergy symptoms. OTC Flonase is formulated to provide 24-hour non-drowsy allergy relief and will be available at full-prescription strength, beginning in early 2015.

Once OTC Flonase is available, Carlisle Medical will begin contacting physicians to inform them the OTC version is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



07/07/2014

Re-Launch of Generic Astepro
Released: 07/07/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Astepro (azelastine) has just been re-launched, following FDA approval. Astepro is used to prevent sneezing, runny nose and other symptoms of nasal allegries.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Astepro is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



07/07/2014

Launch of Generic Diovan
Released: 07/07/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Diovan (valsartan) has just been released, following FDA approval. Diovan is used to treat high blood pressure (HBP).

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Diovan is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



06/11/2014

Launch of Generic Actonel 150mg
Released: 06/11/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Actonel 150mg (risendronate sodium tablets) has just been released, following FDA approval. Actonel 150mg is used to treat or prevent osteoporosis in men and women. It is also used to treat Paget's disease of bone. It works by altering the cycle of bone formation and breakdown in the body.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Actonel 150mg is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



06/11/2014

Launch of Generic Testim® 1% gel
Released: 06/11/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Testim® 1% gel (testosterone gel) has just been released, following FDA approval. Testim® 1% gel is used by adult men to treat the symptoms of low testosterone levels or no testosterone levels.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Carlisle Medical will be contacting physicians to inform them that the generic version of Testim® 1% gel is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review Service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



05/29/2014

Launch of Generic Pennsaid 1.5%
Released: 05/29/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Pennsaid 1.5% (diclofenac sodium topical solution) has just been released, following FDA approval. Pennsaid is a non-steroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Pennsaid 1.5% is available. Management is our focus, as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



05/27/2014

New Medication Update: Nexium® 24HR
Released: 05/27/2014
By: Carl Richie, Pharmacy Manager

Pfizer, Inc. has announced the introduction in the U.S. of over-the-counter (OTC) Nexium® 24HR. The active ingredient in Nexium® 24HR is esomeprazole 20mg, which is a part of a group of medications called proton pump inhibitors or PPIs. Nexium® 24HR works by blocking acid at the source.

Nexium® 24HR is not AB rated. Physicians may consider prescribing Nexium® 24HR as an alternative to Nexium® 20mg. At this time, it is anticipated that a generic launch of Nexium® 40mg will occur later in 2014.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that Nexium® 24HR is available. Management is our focus as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



05/19/2014

Launch of Generic Exalgo® Extended Release Tablets
Released: 05/19/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Exalgo® extended release tablets (hydromorphone hydrochloride) has just been released, following FDA approval. Exalgo® is prescribed to treat moderate to severe pain.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Exalgo® (hydromorphone hydrochloride) is available. Management is our focus as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



04/18/2014

Launch of Generic Lovaza® Capsules
Released: 04/18/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Lovaza® capsules (omega-3-acid ethyl esters) has just been released, following FDA approval. Lovaza® is prescribed to treat high cholesterol.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Lovaza® (omega-3-acid ethyl esters) is available. Management is our focus as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.




04/15/2014

Lunesta Generic Release
Released: 04/15/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Lunesta tablets (eszopiclone) has been released, following FDA approval. Lunesta is a widely prescribed sedative used to treat insomnia. During the 180-day exclusivity period, multiple companies have received FDA approval to market eszopiclone in various strengths.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Lunesta (eszopiclone) is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



03/01/2014

New Medication - Zohydro
Released: 03/01/2014
By: Carl Richie, Pharmacy Manager

Zohydro, a new opioid narcotic painkiller, has recently been released in the 10mg, 15mg, and 20mg strengths. Higher strengths have not yet been released.

Zohydro has a CII classification and may have serious side effects, if not used properly. Even though the medication is meant to release hydrocodone slowly over a twelve-hour period, the pill could be tampered with to release a large dose all at once. Therefore, abuse is of a concern and extreme caution is required for its use.

We recommend this medication require prior authorization for all fills.



02/04/2014

Generic Avinza Capsules
Released: 02/04/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Avinza capsules (Morphine Sulphate capsules, extended release) has just been released, following FDA approval. The extended form of this medicine is used for round-the-clock treatment of pain. This form of morphine is not for use on an as-needed basis for pain.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Avinza (Morphine Sulphate) is available. Management is our focus as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



01/13/2014

Micardis Generic Release
Released: 01/13/2014
By: Carl Richie, Pharmacy Manager

The generic equivalent of Micardis tablets (telmisartan) has just been released, following FDA approval. Micardis is prescribed to treat high blood pressure. During the 180-day exclusivity period, multiple companies have received FDA approval to market telmisartan in various strengths.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Micardis (telmisartan) is available. Management is our focus as we are deeply involved in evaluating generic usage, as well as alternative therapies. We provide this on an ongoing basis through our Prescription Review service.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.



01/02/2014

Generic Detrol LA Capsules®
Released: 01/02/2014
By: Carl Richie, Pharmacy Manager

On Thursday, January 2, Teva Pharmaceuticals launched the generic equivalent of Detrol LA® extended-release capsules (tolterodine tartrate) following FDA approval.

Detrol® LA (tolterodine ER) is a long-acting drug used to treat overactive bladder symptoms.



12/11/2013

Cymbalta® Delayed-Release Capsule Launch
Released: 12/11/2013
By: Carl Richie, Pharmacy Manager

Effective December 11, 2013, the generic equivalent of Cymbalta® delayed-release capsules (duloxetine HCI) was released, following FDA approval. Cymbalta® is one of the most widely prescribed treatments for depression, anxiety and other disorders. During the 180-day exclusivity period, multiple companies have received FDA approval to market duloxetine HCI in various strengths.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand-name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand-name drugs.

Over the next 30 days, Carlisle Medical will be contacting physicians to inform them that the generic version of Cymbalta® (duloxetine HCI) is available.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com



11/11/2013

Launch of Generic Aciphex® 20mg Tablets
Released: 11/11/2013
By: Carl Richie, Pharmacy Manager

On Friday, November 8, Lupin Pharmaceuticals, Inc., launched the generic equivalent of Aciphex® delayed-release tablets 20mg (rabeprazole sodium) following the expiration of pediatric exclusivity.

Rabeprazole sodium is used for the short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative GERD; maintaining healing and reducing relapse rates of heartburn symptoms in patients with erosive or ulcerative GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD. Estimated annual U.S. brand sales are $1.3B.



09/24/2013

Launch of Generic Niaspan® Extended-Release Tablets
Released: 09/24/2013
By: Carl Richie, Pharmacy Manager

Teva Pharmaceuticals has launched generic Niaspan® Extended-Release Tablets, which received FDA Approval in April 2005 and can now be released based on a settlement with the brand manufacturer.

Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Estimated annual U.S. brand sales of this product are $1.129 billion.



09/24/2013

Launch of Generic Nitrolingual® Pump Spray
Released: 09/24/2013
By: Carl Richie, Pharmacy Manager

On September 20, 2013, Perrigo received final FDA approval and launched the generic equivalent of Arbor’s brand product Nitrolingual® Pump Spray. Perrigo is exclusive in the market, with 180 day exclusivity on this product. Estimated U.S. annual brand sales for this product are $30M.

Nitrolingual® Pump Spray (nitroglycerin lingual spray) is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease.




09/17/2013

Generic Lidoderm 5% Patch Launches
Released: 09/17/2013
By: Carl Richie, Pharmacy Manager

Actavis Pharma, Inc. has launched generic Lidoderm® (lidocaine patch 5%), which received FDA approval on August 23, 2012. Inventory will begin arriving in distribution centers on Monday, September 16.

Lidoderm (lidocaine patch 5%) is used to relieve the pain of post-herpetic neuralgia, also referred to as after-shingles pain. Estimated U.S. annual brand sales for this product are $1.3B.

Actavis is exclusive in the market for this new generic, with 180-day exclusivity lasting until March 14, 2014.



08/01/2013

Generic Trilipix Capsules Launch
Released: 08/01/2013
By: Amanda Lafon, Executive Assistant

On July 15, 2013, Global Pharmaceuticals received final FDA approval and commenced shipping for generic Trilipix capsules (fenofibric acid). Abbott's branded product Trilipix capsules had annual U.S. brand sales of approximately $554M for the 12 months ending March 31, 2013, according to IMS Health.

Trilipix capsules are indicated as an adjunct to diet in combination with a statin to reduce triglyceride and increase high-density lipoprotein cholesterol in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal.



05/20/2013

Generic Zomig launches
Released: 05/20/2013
By: Mike Partridge, RPh

On May 14, 2013, Global Pharmaceuticals launched the Authorized Generic (AG) for Zomig and Zomig-ZMT (zolmitriptan and zolmitriptan ODT), Impax Pharma’s branded product. Annual U.S. brand sales for both products combined is $200M.

Zomig and Zomig-ZMT are indicated for the acute treatment of migraine with or without aura in adults, where a clear diagnosis of migraine has been established.




04/03/2013

Generic Zovirax® Launches
Released: 04/03/2013
By: By: Mike Partridge, RPh

On Wednesday, April 3, generic Zovirax® ointment launched. Annual US brand sales of the 30gm tubes of brand Zovirax (acyclovir) were approximately $230M. Acyclovir is indicated in the management of initial genital herpes and in limited non-life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients.


03/19/2013

Generic Luvox® CR Launches
Released: 03/19/2013
By: Mike Partridge, RPh

On March 13, Par Pharmaceuticals received final FDA approval and launched the generic equivalent of Jazz Pharma’s Luvox® CR (fluvoxamine extended release) capsules.

Luvox® CR is indicated for the treatment of obsessive compulsive disorder (OCD), as defined in the DSM-IV. The brand item had U.S. annual sales of approximately $30M.



03/11/2013

Generic Suboxone® Launches
Released: 03/11/2013
By: Mike Partridge, RPh

On March 5, 2013, Amneal Pharmaceuticals LLC announced that its generic equivalent of Suboxone®, Buprenorphine HCl and Naloxone HCl Dihydrate Tablets, 2mg/0.5mg and 8mg/2mg, may be shipped to pharmacies for dispensing and sale to the consumer/patient.

Buprenorphine HCl and Naloxone HCl is the new-to-market generic equivalent of Reckitt Benckiser’s brand product, Suboxone® tablets, and had annual U.S. sales of $1.5B across the product family, according to December 2012 IMS Health market data.

Suboxone® is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. This product was approved under a Risk Evaluation and Mitigation Strategy (REMS) program.



03/11/2013

Generic Zometa® Launches
Released: 03/11/2013
By: Mike Partridge, RPh

Generic Zometa® Launches - On March 5, 2013, Sagent Pharmaceuticals received final FDA approval and launched the generic equivalent of Zometa® (zoledronic acid). Novartis' branded product had annual U.S. sales of approximately $1.2B.

Zometa® is indicated for the treatment of high blood calcium levels (hypercalcemia) that sometimes occur in patients with cancer, as well as the treatment of bone damage caused by Paget's disease, multiple myeloma, and cancers that spread to the bone.



03/04/2013

Generic Antara® Launches
Released: 03/04/2013
By: Mike Partridge, RPh

On Friday, February 22, Mylan received final FDA approval and launched the generic equivalent of Lupin's Antara® (micronized fenofibrate). Annual U.S. brand sales of this product were $53 million.

Antara® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C) triglycerides (TC), and apollpoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.



02/18/2013

Generic Sulfamylon® Launches
Released: 02/18/2013
By: Mike Partridge, RPh

On February 2, 2013, Par Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Mylan’s branded product, Sulfamylon® (mafenide acetate) topical solution. Sulfamylon® had estimated total U.S. annual sales of approximately $8 million.

Sulfamylon® is indicated as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.



02/04/2013

Generic Olux E Foam® Launches
Released: 02/04/2013
By: Mike Partridge, RPh

On February 1, 2013, Perrigo received final FDA approval for and commenced shipping the generic equivalent for Stiefel Laboratories’ branded product, Olux E Foam® (clobetasol propionate). Olux E Foam® had estimated total U.S. annual sales of approximately $40 million.
Olux E Foam® is a corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.



01/28/2013

Generic Clarinex Reditabs® Launch
Released: 01/28/2013
By: Mike Partridge, RPh

On January 23, 2013, Dr. Reddy’s Laboratories commenced shipping the generic equivalent for Merck’s branded product, Clarinex Reditabs® (desloratadine ODT) tablets. Clarinex Reditabs® had estimated total U.S. annual sales of approximately $7 million.
Clarinex Reditabs® is an antihistamine indicated for the relief of the nasal and nonnasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older.



01/28/2013

Generic Bactroban® Launches
Released: 01/28/2013
By: Mike Partridge, RPh

On January 25, 2013, Glenmark received final FDA approval for and commenced shipping the generic equivalent for GlaxoSmithKline’s branded product, Bactroban® (mupirocin) cream. Bactroban® had estimated total U.S. annual sales of approximately $70 million.
Bactroban is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.



01/21/2013

Generic Lamictal XR® Launches
Released: 01/21/2013
By: Mike Partridge, RPh

On January 18, 2013, Par Pharmaceuticals received final FDA approval and commenced shipping the AB-rated generic equivalent for GlaxoSmithKline’s branded product, Lamictal XR® (lamotrigine) tablets. Lamictal XR® had estimated total U.S. annual sales of approximately $262 million.

Lamictal XR is an antiepileptic indicated as adjunctive therapy for primary generalized tonic-clonic seizures or partial onset seizures with or without secondary generalization in patients older than 13 years of age, as well as for conversion to monotherapy in patients older than 13 years of age with partial seizures who are receiving treatment with a single antiepileptic drug.



01/21/2013

Generic Luxiq® Launches
Released: 01/21/2013
By: Mike Partridge, RPh

On January 15, 2013, Perrigo received final FDA approval for and commenced shipping the generic equivalent for GlaxoSmithKlines’s branded product, Luxiq® (betamethasone valerate) foam. Luxiq® had estimated total U.S. annual sales of approximately $30 million.

Betamethasone valerate foam is used to treat skin conditions of the scalp (such as psoriasis, seborrhea). Betamethasone valerate foam works by decreasing the swelling (inflammation), itching, and redness.



01/15/2013

Generic Opana ER® Launches
Released: 01/15/2013
By: Mike Partridge, RPh

On January 7, 2013, Global Pharmaceutical received final FDA approval for and commenced shipping the generic equivalent for Endo’s branded product, Opana ER® (oxymorphone HCL) tablets. Opana ER® had estimated total U.S. annual sales of approximately $25 million.

Opana is an opioid agonist indicated for the relief of moderate to severe pain in patients requiring continuous around the clock opioid treatment for an extended period of time



01/15/2013

Generic Duetact® Launches
Released: 01/15/2013
By: Mike Partridge, RPh

On January 8, 2013, Sandoz received final FDA approval for and commenced shipping the generic equivalent for Takeda’s branded product, Duetact® (pioglitazone HCL) tablets. Duetact® had estimated total U.S. annual sales of approximately $30 million.

Duetact is an oral antihyperglyemic agent that acts primarily by decreasing insulin resistance, and is used in the management of type 2 diabetes.



01/07/2013

Generic of Dilantin® Chewable Tablets Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On December 27, 2012, Mylan received final FDA approval for the generic equivalent of Pfizer’s Dilantin® Chewable Tablets. Dilantin Infatabs® had estimated total U.S. annual sales of approximately $16.5 million for the twelve months ending September 2012, according to IMS.

Dilantin Infatabs® are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures. However, like many other seizure medications, it may also be effective for nerve pain treatment (though it is not approved for this use).



01/07/2013

Generic of Maxalt® Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On December 31, 2012, Apotex received final FDA approval for and commenced shipping the generic equivalent for Merck’s branded product, Maxalt® (rizatriptan benzoate) tablets. Maxalt® had estimated total U.S. annual sales of approximately $336 million.

Maxalt® is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.



01/07/2013

Generic of Maxalt-MLT® Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On December 31, 2012, Mylan received final FDA approval for and commenced shipping the generic equivalent for Merck’s branded product, Maxalt-MLT® (rizatriptan benzoate) orally disintegrating tablets. Maxalt-MLT® had estimated total U.S. annual sales of approximately $270 million.

Maxalt-MLT is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.



01/07/2013

Generic of Propecia® Launches
Released: 01/07/2013
By: Mike Partridge, RPh

On January 2, 2013, Dr. Reddy’s commenced shipping the generic equivalent for Merck’s branded product, Propecia® (finasteride) tablets. Propecia® had estimated total U.S. annual sales of approximately $150 million.

Propecia is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.



11/21/2012

Generic Gabitril® Launches
Released: 11/21/2012
By: Mike Partridge, RPh

On October 18, Caraco received final FDA approval and launched the generic equivalent of Teva Pharmaceutical’s branded product Gabitril®. Gabitril® is indicated as adjunctive therapy in adults and children 12 years or older in the treatment of partial seizures.
Note: Gabitril® can also be prescribed to relieve nerve pain and muscle spasticity.



11/19/2012

Update on Generic Vicodin®
Released: 11/19/2012
By: Mike Partridge, RPh

By January 1, 2014, FDA is limiting the amount of acetaminophen to 325mg per pill or 15ml dose. Any products with more than 325mg acetaminophen will no longer be available on the market after this date.
Abbott Laboratories recently announced the launch of a reformulated Vicodin. This reformulation brings down the acetaminophen content to 300mg per tablet. Abbott Laboratories is marketing their brand product as generic.



11/19/2012

Generic Arthrotec®
Released: 11/19/2012
By: Mike Partridge, RPh

On November 1, 2012, Greenstone commenced shipping the Authorized Generic (AG) for Pfizer’s branded product Arthrotec® (diclofenac sodium, misoprostol). For the twelve months ending May 31, 2012, Arthrotec® had total U.S. sales of approximately $130 million according to IMS Health data.
Arthrotec® is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients in high risk of developing NSAID-induced gastric and duodenal ulcers and their complications.



03/08/2012

March Generic Drug Releases
Released: 03/08/2012
By: Theron Mindek

Generic Equivalent of Geodon® Launches

Dr. Reddy's Laboratories received final FDA approval and launched their AB-rated generic of Pfizer's Geodon® (ziprasidone hydrochloride capsules).

Geodon (ziprasidone) is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.

ZIPRASIDONE CAP 20MG
ZIPRASIDONE CAP 40MG
ZIPRASIDONE CAP 60MG
ZIPRASIDONE CAP 80MG


This generic is in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy.



02/29/2012

February Generic Drug Releases
Released: 02/29/2012
By: Theron Mindek

LAUNCH OF GENERIC LEXAPRO®

As of February 29, an authorized generic for escitalopram oxalate has become available. This product is the generic version of Forest Laboratories’ branded product, Lexapro®.
Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age.

This generic will be in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy as of 3/14/2012.



01/09/2012

January Generic Drug Releases
Released: 01/09/2012
By: Theron Mindek

Generic Ritalin LA® Capsules Launched

Actavis Group commenced shipping their AB rated generic equivalent of Novartis' Ritalin LA® Capsules in the 20, 30, and 40mg strengths (100-count bottle).
Ritalin LA® (methylphenidate hydrochloride) extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD)
This drug is classified as a CII medication. New prescriptions (hard copies) will be required at the pharmacy in order to dispense the new generic version.


Generic Clobex® Lotion and Shampoo Launched

Actavis Group commenced shipping their AB rated generic equivalent of Clobex® (Clobetasol) lotion and shampoo 0.05% in the 2 and 4 ounce sizes for the lotion, and 4 ounce size for the shampoo.
Clobex® (clobetasol propionate) Shampoo, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe forms of scalp psoriasis in subjects 18 years of age and older.


Authorized Generic of Ryzolt® Tablets Launched

Rhodes Pharmaceuticals launched tramadol hydrochloride extended-release tablets, the authorized generic (AG) of Purdue Pharma’s branded product, Ryzolt®.
Ryzolt® (tramadol hydrochloride) is indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time.

All generics are in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy.



12/28/2011

December Generic Drug Releases
Released: 12/28/2011
By: Theron Mindek

Generic — Lipitor®

On November 30th, Watson launched the authorized generic version of Lipitor® (atorvastatin calcium) tablets. Watson has received all FDA approvals.
Lipitor® is a prescription medicine that is used along with a low-fat diet. It lowers the LDL ("bad") cholesterol and triglycerides in blood, and can raise HDL ("good") cholesterol as well. Lipitor can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as age, smoking, high blood pressure, low HDL, or family history of early heart disease.

Generic — Caduet®

On November 30th, Mylan commenced shipping their AB rated version of Caduet® (amlodipine besylate, atoravastatin calcium) tablets marketed by Pfizer.
Caduet is a prescription drug that combines two medicines, Norvasc® (amlodipine besylate) and Lipitor® (atorvastatin calcium). Norvasc is used to treat high blood pressure (hypertension), chest pain (angina), or blocked arteries of the heart (coronary artery disease); Lipitor is used along with a low-fat diet to lower the LDL (“bad” cholesterol) and triglycerides in the blood. It can raise the HDL (“good” cholesterol) as well.

Generic — Combivir®

On December 27th, Teva Pharmaceuticals has received final FDA approval and began shipping lamivudine and zidovudine tablets, the generic version of GlaxoSmithKline’s branded product, Combivir®.
The combination of lamivudine and zidovudine is used to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Lamivudine and zidovudine are in a class of antiviral medications called synthetic nucleoside analogues

The above generics are in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy.



11/21/2011

November Generic Drug Release
Released: 11/21/2011
By: Theron Mindek

Authorized Generic of Kadian® Capsules Launches

On November 10th, Watson received final FDA approval and launched their generic version of Kadian® capsules.

-MORPHINE SU ER CAP 20, 30, 50, 60, 80,100MG

Morphine is used to relieve moderate to severe pain. Morphine long-acting tablets and capsules are only used by patients who are expected to need medication to relieve moderate to severe pain around-the-clock for longer than a few days.

Generic Equivalent of Xyzal® Oral Solution Launched

On November 7th, Perrigo Company announced that they received final FDA approval for their Abbreviated New Drug Application (ANDA) for levocetirizine dihydrochloride oral solution. This product is the AB-rated generic version of UCB Pharmaceutical's branded product, Xyzal® oral solution.

-LEVOCET DIHY OS 2.5/55OZ

Xyzal oral solution is indicated for the treatment of indoor and outdoor allergies.

Both Generics are in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy



11/18/2011

October Generic Drug Release
Released: 11/18/2011
By: Theron Mindek

Teva announced on October 24th that they received final FDA approval to market, distribute, and sell the blockbuster generic equivalent of Zyprexa® (olanzapine) tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Olanzapine is used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older, and is also used to treat bipolar disorder in adults and teenagers 13 years of age and older.

Also on October 24th, Par Pharmaceuticals announced on October 24th that they received final FDA approval to market, distribute, and sell their AB-rated generic equivalent of Zyprexa® Zydis ODT (olanzapine) tablets OLANZAP OD TAB 5mg, 10mg, 15mg,and 20mg 30. Olanzapine is used to treat the symptoms of schizophrenia in adults and teenagers 13 years of age and older, and is also used to treat bipolar disorder in adults and teenagers 13 years of age and older

Both Generics are in stock and available to all claimants covered by Carlisle Medical Home Delivery Pharmacy.



07/21/2011

July 2011 Generics
Released: 07/21/2011
By: Jerry M. Partridge, RPh

The following workers compensation related generics are now available to the market:
Oxymorphone Hydrochloride Extended-Release 7.5mg & 15mg Tablet (generic for Opana ER)
Alfuzosin HCL 10mg Tablet (generic for Uroxatral)



07/20/2011

June 2011 Generics
Released: 07/20/2011
By: Jerry M. Partridge, RPh

The following workers compensation related generics are now available to the market:
Triamcinolone Acetonide 55 mcg Spray (generic for Nasacort AQ)
Levofloxacin 250mg, 500mg and 750mg Tablet (generic for Levaquin)



07/19/2011

May 2011 Generics
Released: 07/19/2011
By: Jerry M. Partridge, RPh

The following workers compensation related generics are now available to the market:
Methylphenidate HCL 18mg, 27mg, 36mg, & 54mg Extended-Release 24 tablet (generic for Concerta)
Cyclobenzaprine HCL 15mg & 30 mg Extended-Release 24 Capsule (generic for Amrix)
Carbamazepine 100mg, 200mg and 300mg CPMP 24HR (generic for Carbatrol)



05/31/2011

April 2011 Generics
Released: 05/31/2011
By: Jennifer Fuqua

The following workers compensation related generics are now available to the market:
Paroxetine HCL Extended-Release Tablets, 37.5mg - Mylan Pharmaceuticals, Inc. (generic for Paxil CR Tablets)
Cyclobenzaprine Hydrochloride Extended-Release Capsules, 15mg and 30mg - Mylan Pharmaceuticals, Inc. (generic for Amrix Extended-Release Capsules)



05/31/2011

March 2011 Generics
Released: 05/31/2011
By: Jennifer Fuqua

The following workers compensation related generics are now available to the market:
Epinastine Hydrochloride Ophthalmic Solution, 0.05% - Cypress Pharmaceutical, Inc. (generic for Elestat Ophthalmic Solution)



05/31/2011

February 2011 Generics
Released: 05/31/2011
By: Jennifer Fuqua

The following workers compensation related generics are now available to the market:
Gabapentin Oral Solution, 250mg/5ml - Hi-Tech Pharmacal Co., Inc. (generic for Neurontin Oral Solution)



05/30/2011

January 2011 Generics
Released: 05/30/2011
By: Jerry M. Partridge, RPh

The following workers compensation related generics are now available to the market:
Amlodipine Besylate/Benazepril Oral Capsule 10mg-40 & 5mg-40m (generic for Lotrel)



03/21/2011

December 2010 Generics
Released: 03/21/2011
By: Jennifer Fuqua

The following workers compensation related generics are now available to the market:

Zolpidem Tartrate extended-release tablets, 12.5mg - ANCHEN PHARMACEUTICALS, INC. (generic for Ambien CR tablets, 12.5mg)

Levofloxacin Ophthalmic Solution, 0.5% - APOTEX INC./NEXUS PHARMACEUTICALS, INC./AKORN INC. (generic for Quixin Ophthalmic Solution)

Doxycycline Hyclate delayed-release tablets USP, 75mg (BASE) and 100mg (BASE) - IMPAX LABORATORIES, INC./MYLAN PHARMACEUTICALS, INC. (generic for Doryx Tablets)



12/29/2010

July 2010 Generic Drugs
Released: 12/29/2010
By: Tina Neylon

Doxycycline delayed-released capsules, 40 mg (30 mg immediate release and 10 mg delayed-released) – MYLAN PHARMACEUTICALS, INC. – Oracea Capsules – 07/01/10
Clindamycin Palmitate Hydrochloride for oral solution USP, 75 mg (BASE)/5ML – PADDOCK LABORATORIES, INC. – Cleocin for Oral solution – 07/07/10
Desloratadine Orally Disintegrating Tablets, 2.5 mg and 5 mg – DR. REDDY’S LABORATORIES LIMITIED – Clarinex Reditabs – 07/12/10



12/29/2010

August 2010 Generic Drugs
Released: 12/29/2010
By: Tina Neylon

Venlafaxine Hydrochloride Extended-Release tablets, 37.5 mg (BASE), 75 mg (BASE) and 150 mg (BASE) – SUN PHARMA GLOBAL, INC. – Venlafaxine HCL Extended-Release Tablets – 08/18/10
Atomoxetine Hydrochloride Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg – ACTAVIS ELIZABETH LLC – Strattera Capsules – 08/30/10
Atomoxetine Hydrochloride Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg – SUN PHARMA GLOBAL, INC. – Fzestrattera Capsules – 08/30/10
Atomoxetine Hydrochloride Capsules, 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, and 100 mg – MYLAN PHARMACEUTICALS, INC. – Strattera Capsules – 08/30/10



08/03/2010

June 2010 Releases
Released: 08/03/2010
By: Tina Neylon

Chlorzoxazone Tablets USP, 375 mg and 750 mg – MIKART, INC. – Brand Name: PARAFON FORTE DSC CAPLETS – approval date 6/1/2010 (Muscle relaxant)


08/03/2010

June 2010 Releases
Released: 08/03/2010
By: Tina Neylon

Oxymorphone Hydrochloride Extended-Release Tablets, 5 mg, 10 mg, 20 mg and 40 mg – IMPAX LABORATORIES, INC. – Brand Name: OPANA ER TABLETS – approval date 6/14/2010 (Pain relief)


03/18/2010

February 2010 – Generic Drug Updates
Released: 03/18/2010
By: Tina Neylon

DESLORATADINE TABLETS, 5 mg, Orchid Healthcare, Clarinex tablets (Antihistamine)


02/17/2010

November 2009 Generic Drug Releases
Released: 02/17/2010
By: Tina Neylon

Ketorolac Tromethamine Ophthalmic solution, .4%. by APOTEX, INC.
Brand Name: ACULAR LS Ophthalmic solution

Ketorolac Tromethamine Ophthalmic solution, .5% by ALCON, INC.
Brand Name: ACULAR Ophthalmic solution

Ketorolac Tromethamine Ophthalmic solution, .4%. by ALCON, INC.
Brand Name: ACULAR LS Ophthalmic solution

Ketorolac Tromethamine Ophthalmic solution, .5% by ALCON, INC.
Brand Name: ACULAR Ophthalmic solution

Ketorolac Tromethamine Ophthalmic solution, .4%. by ALCON, INC.
Brand Name: ACULAR LS Ophthalmic solution

Ketorolac Tromethamine Ophthalmic solution, .5%. by SUN PHARMA GLOBAL INC.
Brand Name: ACULAR LS Ophthalmic solution

Lansopraxole Delayed-release capsules USP, 15 mg and 30 mg by TEVA PHARMACEUTICALS USA
Brand Name: Prevacid Delayed-release capsules

Lansopraxole Delayed-release capsules USP, 15 mg and 30 mg by MATRIX LABORATORIES LIMITED
Brand Name: Prevacid Delayed-release capsules

Hydrochloride Extended-release tablets, 100 mg and 200 mg by PAR PHARMACEUTICAL, INC.
Brand Name: Ultram ER tablets, 100 mg and 200 mg



10/31/2009

October 2009 - Generic Drug Updates
Released: 10/31/2009
By: Tina Neylon

Polyethylene Glycol 3350 powder for solution, (OTC), 17 grams/scoopful by Kremers Urban Development Company for Miralax for oral solution (constipation)

Buprenorphine Hydrochloride Sublingual tablets, 2 MG (BASE) and 8 MG (BASE), by Roxane Laboratories, Inc. for Subutex Sublingual Tablets (narcotic dependence)

Oral Transmucosal Fentanyl Citrate, 200, 10 MCG, 400 MCG, 600 MCG, 800 MCG, 1200 MCG and 16 MCG by Mallinckrodt, Inc., for Actiq Oral Transmucosal Lozenge (chronic pain)




09/30/2009

September Generic Releases
Released: 09/30/2009
By: Tina Neylon

Temazepam Capsules USP,7.5 MG by Mutual Pharmaceutical Company, Inc. for Restoril Capsules (Anxiety)


08/31/2009

August Generic Releases
Released: 08/31/2009
By: Diane Marston

Clonidine Transdermal System, USP0.1 MG/Day, 0.2 MG/Day and 0.3 MG/Day by Aveva Drug Delivery Systems, for Catapres-TTS (blood pressure).


07/31/2009

July Generic Release Date
Released: 07/31/2009
By: Diane Marston

Triamcinolone Acetonide Nasal Spray, 0.055 MG/Spray by Barr Laboratories, Inc., for Nasacort AQ Nasal Spray 0.055 MG/Spray (anti-inflammatory).


06/30/2009

June Generic Releases
Released: 06/30/2009
By: Diane Marston

Omeprazole Magnesium delayed release capsules, (OTC) 20 MG (base) for Prilosec OTC delayed release capsules (heartburn).
Oxcarbazepine oral suspension, 200 MG/5ML for Trileptal oral suspension (seizures).



04/30/2009

April Generic Releases
Released: 04/30/2009
By: Diane Marston

Topiramate Capsules (Sprinkle), 15 MG and 25 MG by Barr Laboratories, Inc., for Topamax Sprinkle Capsules (nerve pain/anti-convulsant)
Topiramate Capsules (Sprinkle), 15 MG and 25 MG by Cobalt Laboratories, Inc., for Topamax Sprinkle Capsules (nerve pain/anti-convulsant)
Azelastine Hydrochloride Nasal Solution (nasal spray), 0.1% [125 mcg (base)/spray] by Apotex Inc for Astelin Nasal Spray
Risperidone Orally Disintegrating Tablets, 0.25 MG, 0.5 MG, 2 MG, 3 MG and 4 MG by Kali Laboratories, Inc., for Risperdal-M Tab (Orally disintegrating tablet) – antipsychotic



03/31/2009

March Generic Releases
Released: 03/31/2009
By: Diane Marston

Levalbuterol Inhalation Solution USP, 0.25% for Xopenex Inhalation Solution (lung conditions).
Ibuprofen Capsules, 200 MG for Advil Liquid Gels Capsules (liquid filled capsule).
Topiramate Tablets, 25 MG, 50 MG, 100 MG and 200 MG for Topamax Tablets (nerve pain/anti-convulsant)
Carbamazepine Extended-Release Tablets USP, 100 MG, 200 MG and 400 MG for Tegretol-XR Tablets (anti-convulsant).



01/31/2009

January Generic Releases
Released: 01/31/2009
By: Diane Marston

The following workers compensation related generics are now available to the market:

Alprazolam orally disintegrating tablets, o.25 mg, 0.5 mg, 1 mg, and 2 mg for Nirvam orally disintegrating tablets (anti-anxiety).



11/30/2008

November Generic Releases
Released: 11/30/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Levetiracetam Tablets, 250 MG, 500 MG, and 750 MG for Keppra Tablets (epilepsy)
Budesonide Inhalation Suspension for Pulmicort Respules Inhalation Suspension (asthma)



10/31/2008

October Generic Releases
Released: 10/31/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Dorzolamide HCL & Timolol Maleate Ophthalmic Solution for Cospot Ophthalmic Solution (glaucoma)



09/30/2008

September Generic Releases
Released: 09/30/2008
By: Diane Marston

The following workers compensation related generic releases are now available to the market:

Galantamine Hydrobromide Extended Release Capsules 8 MG, 16 MG, and 24 MG for Razadyne ER (dementia)



08/31/2008

August Generic Releases
Released: 08/31/2008
By: Diane Marston

The following workers compensation related generics are now available:

Galantamine Tablets, 4 MG, 8 MG, and 12 MG for Razadyne Tablets (dementia)



07/31/2008

July Generic Releases
Released: 07/31/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Divalproex Sodium Delayed-Release Tablets, 125 MG, 250 MG, and 500 MG for Depakote Delayed Release Tablets (depression and seizures)



06/30/2008

June Generic Releases
Released: 06/30/2008
By: Diane Marston

The following workers compensation generics are now available to the market:

Zalepon Capsules, 5 MG and 10 MG for Sonata Capsules (sedative)

Risperidone Tablets USP, 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG and 4 MG for Risperdal Tablets (bipolar disorder)



05/31/2008

May Generic Releases
Released: 05/31/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Ropinirole Hydrochloride Tablets .25 MG, .5 MG, 1 MG, 2 MG, 3 MG, and 4 MG for Requip (Parkinsons Disease and Restless Leg Syndrome)



04/30/2008

April Generic Releases
Released: 04/30/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Lithium Carbonate Capsules USP, 600 MG for Lithium Carbonate Capsules USP (depression)
Donepezil Hydrochloride Tablets 5 MG and 10 MG for Aricept Tablets (dementia)



02/28/2008

February Generic Releases
Released: 02/28/2008
By: Diane Marston

The following workers compensation related generics are now available to the market:

Alendrontate Sodium Tablets for Fosamax Tablets (osteoporosis)
Pramipexole Dihydrochloride Tablets for Mirapex Tablets (Restless Leg Syndrome and Parkinson Disease)



12/31/2007

December Generic Releases
Released: 12/31/2007
By: Diane Marston

The following workers compensation related generics are now available to the market:

Extended Phenytoin Sodium Capsules, USP 30 MG for Dilantin (antiepileptic drug)



10/31/2007

October Generic Releases
Released: 10/31/2007
By: Diane Marston

The following workers compensation related generics are now available to the market:

Albuterol Sulfate for Accundeb Inhalation Solution (Asthma)
Nifedipine Extended Release Tablets USP, 90 MG for Procardia XL Tablets (Heart Disease)
Hydrocodone Bitrartrate and Ibuprofen Tablets, 2.5 MG for Vicoprofen Tablets (anti-inflammatory and pain reliever)



09/12/2007

September Generic Releases
Released: 09/12/2007
By:

The following workers compensation related generics are now available to the market:

Albuterol/Ipratropium for Duoneb (Inhaler)
Metoprolol ER for Toprol XL (Hypertension)
Carvedilol Tabs for Coreg (Hypertension)



05/25/2007

May Generic Releases
Released: 05/25/2007
By:

The following workers compensation related generics are now available to the market:

Amlodipine Besylate for Norvasc (hypertension)
Zolpidem Tartrate for Ambien (insomnia)
Amlodipine Benazepril for Lotrel (hypertension)



04/02/2007

New Generics
Released: 04/02/2007
By:

The following workers compensation related generics are now available to the market:

Propranolol/Hydrochloride for Inderol (hypertension)
Trandolapril for Tarka (hypertension)
Moexipril/Hydrochlorothiazide for Univasc (hypertension)




12/31/2006

Workers Compensation Generic Drugs Released in 12/06
Released: 12/31/2006
By:

The following workers compensation related generics are now available to the market:

Metoprolol ER for Toprol-XL (hypertension)
Amoxicillin for Amoxil (antibiotic)
Lisin+HCTZ for Prinizine (hypertension)
Penicil-VK for V-Cillin K



 
Newsletter Subscription
Newsletter Preferences
 
© Copyright 2020 Carlisle Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer